A once-daily triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; ICS/LAMA/LABA*) in a single inhaler significantly reduces the risk of all-cause mortality compared with a dual therapy of UMEC/VI (LAMA/LABA) in chronic obstructive pulmonary disease (COPD) patients with a history of moderate or severe exacerbations, confirm the latest results of the IMPACT** study.
Both antibiotics and systemic corticosteroids reduce treatment failure rates in patients with chronic obstructive pulmonary disease (COPD), regardless of severity of exacerbations, according to a systematic review and meta-analysis of randomized trials.
Use of antibiotics and systemic corticosteroids can help decrease treatment failure in adults with mild-to-severe exacerbation of chronic obstructive pulmonary disease (COPD), results of a systematic review and meta-analysis have shown.
A blood eosinophil value of <0.144 × 109/L on admission or <2 percent is predictive of a longer hospital length of stay (LOS) among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), suggests a study.
Chronic obstructive pulmonary disease (COPD) patients with comorbid chronic cough appear to exhibit a more severe disease in terms of accompanying respiratory symptoms and healthcare utilization, lung function, and inflammation in blood, according to a study.
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Exposure to inhaled corticosteroid therapy for chronic obstructive pulmonary disease (COPD) in the long term may be detrimental to patients, being associated with elevated risks of diabetes, its progression and osteoporosis, as shown in a study.
Patients with chronic obstructive pulmonary disease (COPD) who initiate treatment with inhaled corticosteroids (ICS) may have an elevated risk of developing type 2 diabetes mellitus (T2DM), according to a matched cohort study.